Randomized controlled trial on the safety of protein restriction in patients with conservative chronic kidney disease patients

Randomized controlled trial on the safety of protein restriction in patients with conservative chronic kidney disease patients - Randomized controlled trial on the safety of protein restriction in patients with conservative chronic kidney disease patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050234

Enrollment

190

Registered

2023-02-05

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

conservative chronic kidney disease patients

Interventions

If assigned to the protein-restricted group, nutritional guidance will be given with the following goals: patients with eGFR 44 ml/min/1.73 m2 or less will be protein restricted with a target protein

patients with eGFR 45-59 ml/min/1.73 m2 or less will be protein restricted with a target protein intake of 0.8-1.0 g/kg (BW)/day. Ideal body weight (height(m)*height(m)*22) should be used. If assigne

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are at least 50 years of age and have given written consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients who are expected to receive renal replacement therapy within one year Patients with urinary protein >3.5 g/gCr Patients on steroids or expected to be on steroids Patients with pacemakers or ICDs Patients who the investigator determines to be inappropriate as research subjects

Design outcomes

Primary

Measure	Time frame
Change from baseline in skeletal muscle mass index at 1 year	—

Secondary

Measure	Time frame
Change from baseline in grip strength, SPBB, eGFR, and urinary protein at 1 year	—

Countries

Japan

Contacts

Public ContactNobuhiro Hashimoto

Osaka General Medhical Center Kidney disesase and Hypertention

kyuseisogo@opho.jp0666921201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026